Plus Therapeutics (PSTV) 10-K 29 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Jan. 31, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Trading Symbol	CYTX
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 9
Entity Common Stock, Shares Outstanding		16,326,116
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,261	$ 9,550
Accounts receivable, net of reserves of $185 in 2018 and $167 in 2017	286	145
Restricted cash	40	675
Inventories, net	2,947	3,183
Other current assets	1,114	1,311
Total current assets	9,648	14,864
Property and equipment, net	2,559	3,052
Other assets	1,905	2,570
Intangibles, net	5,957	7,207
Goodwill	3,922	3,922
Total assets	23,991	31,615
Current liabilities:
Accounts payable and accrued expenses	3,357	4,790
Current portion of long-term obligations, net of discount	14,202	13,624
Total current liabilities	17,559	18,414
Deferred revenues	167	94
Long-term deferred rent and other	124	107
Warrant liability	916
Total liabilities	18,766	18,615
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 30,223 shares issued; 4,606 and 2,431 shares outstanding in 2018 and 2017, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 14,830,414 and 5,782,573 shares issued and outstanding in 2018 and 2017, respectively	15	6
Additional paid-in capital	418,375	413,356
Accumulated other comprehensive income	1,218	1,387
Accumulated deficit	(414,383)	(401,749)
Total stockholders’ equity	5,225	13,000
Total liabilities and stockholders’ equity	$ 23,991	$ 31,615

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Accounts receivable, reserves	$ 185	$ 167
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	30,223	30,223
Preferred stock, shares outstanding (in shares)	4,606	2,431
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	14,830,414	14,830,414
Common stock, shares outstanding (in shares)	5,782,573	5,782,573

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Revenues	$ 3,671	$ 2,689
Cost of product revenues	$ 1,148	$ 1,318
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Amortization of intangible assets	$ 1,225	$ 1,225
Gross profit	1,298	146
Development revenues:
Government contracts and other	2,983	3,722
Total development revenues	2,983	3,722
Operating expenses:
Research and development	8,622	11,678
Sales and marketing	2,018	3,593
General and administrative	6,339	7,594
In process research and development acquired from Azaya	0	1,686
Total operating expenses	16,979	24,551
Operating loss	(12,698)	(20,683)
Other income (expense):
Interest income	43	33
Interest expense	(1,922)	(2,049)
Other income, net	180	13
Change in fair value of warrants	2,233	0
Issuance cost of warrants	(470)	0
Total other expense	64	(2,003)
Net loss	(12,634)	(22,686)
Beneficial conversion feature for convertible preferred stock	(2,487)	(3,977)
Net loss allocable to common stockholders	$ (15,121)	$ (26,663)
Basic and diluted net loss per share allocable to common stockholders	$ (1.74)	$ (8.23)
Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders	8,692,551	3,238,983
Comprehensive loss:
Net loss	$ (12,634)	$ (22,686)
Other comprehensive income – foreign currency translation adjustments	(169)	129
Comprehensive loss	(12,803)	(22,557)
Product [Member]
Revenues:
Revenues	2,671	2,689
License [Member]
Revenues:
Revenues	$ 1,000	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]Series C Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Convertible Preferred Stock [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016	$ 10,986						$ 2			$ 388,789			$ 1,258	$ (379,063)
Balance (in shares) at Dec. 31, 2016							2,170,789
Share-based compensation	753									753
Issuance of common stock under employee stock purchase plan	1									1
Issuance of common stock under employee stock purchase plan (in shares)							120
Sale/Issuance of common stock	12,716	$ 8,767					$ 1			12,715	$ 8,767
Sale/Issuance of common stock (in shares)					10,000		1,223,708
Conversion of Convertible Preferred Stock into common stock		23						$ 3			20
Conversion of Convertible Preferred Stock into common stock (share)					(7,569)			2,270,632
Issuance of common stock as part of Azaya Therapeutics acquisition, net	2,311									2,311
Issuance of common stock as part of Azaya Therapeutics acquisition, net (shares)							117,324
Beneficial conversion feature related to Series B Convertible Preferred Stock		3,977									3,977
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock		$ (3,977)									$ (3,977)
Foreign currency translation adjustment and accumulated other comprehensive income	129												129
Net loss	(22,686)													(22,686)
Balance at Dec. 31, 2017	$ 13,000						$ 6			413,356			1,387	(401,749)
Balance (in shares) at Dec. 31, 2017	5,782,573			2,431			5,782,573
Share-based compensation	$ 355									355
Sale/Issuance of common stock	1,624		$ 3,041				$ 5			1,619		$ 3,041
Sale/Issuance of common stock (in shares)						6,723	4,608,453
Conversion of Convertible Preferred Stock into common stock			8						$ 4			4
Conversion of Convertible Preferred Stock into common stock (share)					(1,320)	(3,228)		396,045	4,043,343
Beneficial conversion feature related to Series B Convertible Preferred Stock			2,487									2,487
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock			$ (2,487)									$ (2,487)
Foreign currency translation adjustment and accumulated other comprehensive income	(169)												(169)
Net loss	(12,634)													(12,634)
Balance at Dec. 31, 2018	$ 5,225						$ 15			$ 418,375			$ 1,218	$ (414,383)
Balance (in shares) at Dec. 31, 2018	5,782,573			4,606			14,830,414

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (12,634)	$ (22,686)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,004	2,151
Amortization of deferred financing costs and debt discount	578	707
In process research and development acquired from Azaya Therapeutics	0	1,686
Change in fair value of warrants	(2,233)	0
Allocation of issuance cost associated with warrants	470	0
Provision for doubtful accounts	18	0
Provision for excess inventory	463	340
Share-based compensation expense	355	753
Loss (gain) on asset disposal	36	(42)
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	(173)	1,129
Inventories	475	251
Other current assets	85	(593)
Other assets	23	(94)
Accounts payable and accrued expenses	(1,532)	(1,817)
Deferred revenues	73	(3)
Long-term deferred rent and other	17	90
Net cash used in operating activities	(11,975)	(18,128)
Cash flows from investing activities:
Proceeds from sale of assets	0	113
Net cash used in investing activities	(133)	(1,383)
Cash flows from financing activities:
Principal payments on long-term obligations	0	(4,720)
Financed capital expenditures	(66)	0
Proceeds from sale of common and preferred stock	8,766	23,613
Costs from sale of common and preferred stock	(1,532)	(2,078)
Net cash provided by financing activities	7,168	16,815
Effect of exchange rate changes on cash and cash equivalents	16	11
Net decrease in cash and cash equivalents	(4,924)	(2,685)
Cash, cash equivalents, and restricted cash at beginning of period	10,225	12,910
Cash, cash equivalents, and restricted cash at end of period	5,301	10,225
Cash paid during period for:
Interest	1,331	1,364
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	8	23
Fair value of Series C and Series B Convertible Preferred Stock beneficial conversion feature	2,487	3,977
Property Plant And Equipment Excluding Research Lab Equipment And Leasehold Improvements [Member]
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(133)	(295)
Assets Purchased from Azaya Therapeutics, Inc. [Member]
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	0	(1,201)
Supplemental schedule of non-cash investing and financing activities:
Common stock issued in payment for the assets acquired	$ 0	$ 2,311

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Operations	1. Organization and Operations The Company Cytori Therapeutics, Inc. (Nasdaq: CYTX) is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Principles of Consolidation The accompanying consolidated financial statements include our accounts and those of our subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company has five wholly-owned subsidiaries located in Japan, United Kingdom, Switzerland, India and Spain that have been established primarily to support our sales and marketing activities in these regions. Amendments to Certificate of Incorporation and Reverse Stock Split On May 23, 2018, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to (i) effectuate a one-for-ten (1:10) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share, without any change to its par value, and (ii) increase the number of authorized shares of the Company’s common stock from 75 million to 100 million shares (which amount is not otherwise affected by the Reverse Stock Split). The Amendment became effective on the filing date. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 61.6 million shares (as of May 23, 2018) to approximately 6.2 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 23.4 million shares to approximately 2.3 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 9.1 million common shares to approximately 0.9 million common shares. The Company’s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented. Certain Risks and Uncertainties Our prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. Our future viability largely depends on our ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that our new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. The development of medical devices for specific therapeutic applications is subject to a number of risks, including research, regulatory and marketing risks. There can be no assurance that our development stage products will overcome these hurdles and become commercially viable and/or gain commercial acceptance. Liquidity and Going Concern We incurred net losses of $12.6 million for the twelve months ended December 31, 2018 31, 2018 31, 2018 Further, the Loan and Security Agreement (defined in Note 7), with Oxford Finance, LCC (“Oxford”), as further described in Note 7, requires the Company to maintain a minimum of $2.0 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement and requires the Company to achieve one of the following by March 29, 2019: (i) enter into an asset sale agreement with a minimum unrestricted net cash proceeds to the Company of $4.0 million; or (ii) enter into a binding agreement for the issuance and sale of its equity securities or unsecured convertible subordinated debt which would result in unrestricted gross cash proceeds of not less than $7.5 million; or enter into a merger agreement pursuant to which the obligations under the Loan Agreement would be paid down to a level satisfactory to Oxford. Based on our cash and cash equivalents on hand of approximately $5.3 million at December 31, 2018 To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed 2018 Rights Offering (defined in Note 10), our Lincoln Park Purchase Agreement (defined in Note 10) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), the ATM program (further defined below) initiated in June 2018, On April 11, 2017, we entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC “Maxim”) relating to the issuance and sale of 0.9 million shares of our common stock. The price to the public in this offering was $11.00 per share. Maxim purchased the shares from us pursuant to the Underwriting Agreement at a price of $10.40 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and offering expenses payable by us. The offering closed purchase up to 94,400 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 84,900 shares at $11.00 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us. On September 5, 2017, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer met the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until March 5, 2018, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until September 4, 2018, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq of our intent to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must have been at least $1.00 per share for a minimum of ten consecutive business days during the second 180-day period. On June 8, 2018, we received written notice from Nasdaq that we had regained compliance with the Nasdaq Stock Market Listing Rule 5500(a)(2) concerning our minimum bid price per share of our common stock. On November 28, 2017, we closed a rights offering originally filed under a Form S-1 registration statement in August 2017 (“2017 Rights Offering”). Pursuant to the 2017 Rights Offering, the Company sold an aggregate of 10,000 units consisting of a total of 10,000 shares of Series B Convertible Preferred Stock, immediately convertible into approximately 3,000,000 shares of common stock and 18,000,000 warrants, exercisable for an aggregate of 1,800,000 shares of common stock at an exercise price of $3.333 per share of common stock, resulting in total net proceeds to the Company of $8.8 million. These warrants became exercisable on May 18, 2018 On June 1, 2018, we entered into a Sales Agreement with B. Riley FBR, Inc. (“B. Riley FBR”) to sell shares of our common stock having an aggregate offering price of up to $6.5 million from time to time, through an “at the market” equity offering program (the “ATM program”) under which B. Riley FBR will act as sales agent. On July 25, 2018, we closed a rights offering originally filed under a Form S-1 registration statement in April 2018 (“2018 Rights Offering”). Pursuant to the 2018 Rights Offering, the Company sold an aggregate of 6,723 units consisting of a total of 6,723 shares of Series C Convertible Preferred Stock, immediately convertible into approximately 8.4 million shares of common stock and 7,059,150 warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.7986 per share, resulting in total net proceeds to the Company of approximately $5.7 million. On August 28, 2018, we received a written notice from Nasdaq indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until February 25, 2019, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must have been at least $1.00 per share for a minimum of ten consecutive business days during the 180-day period. On September 21, 2018, Cytori entered into a purchase agreement and a registration rights agreement, with Lincoln Park, pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $5.0 million of shares of the Company’s common stock over the 24-month period following October 15, 2018, subject to the satisfaction of certain conditions. Through December 31, 2018, the Company sold a total of 0.6 million shares for proceeds of approximately $0.3 million through the Lincoln Park Purchase Agreement. See Note 10 for further discussion on the Lincoln Park Agreement. We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this would negatively affect our ability to achieve corporate growth goals. Should we be unable to raise additional cash from outside sources, this would have a material adverse impact on our operations. The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, valuing warrants, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary. Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2018 and 2017. We maintain our cash at insured financial institutions. Restricted Cash Restricted cash consists of cash invested in certificate of deposits used as collateral for the issuance of letters of credit pursuant to lease agreements for leasing of property at 3020 and 3030 Callan Road, San Diego, CA, which requires us to execute a letter of credit for $40,000 and $0.7 million naming the landlord as a beneficiary as of December 31, 2018 and 2017, respectively. Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or net realizable value. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements. Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. We experienced significant volatility in our share price during the year. During Q3 2018 and Q4 2018, our stock price significantly declined in comparison to the corresponding previous quarters. We performed a valuation of our single reporting unit as of September 30, 2018 (and as updated for the annual test during the fourth quarter in 2018). Based upon the results of our valuation, management concluded that the fair value of the reporting unit exceeded its carrying value. We determined that a blending of the income approach and an option pricing model back-solve was a reasonable approximation of the fair value of the reporting unit. Additionally, a further reduction in our market capitalization could be an indicator of impairment. Given the volatility of our stock price a continued decline in market capitalization could result in an impairment of our goodwill. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture with Olympus Corporation, we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2018 and 2017 are as follows (in thousands): December 31, 2018 December 31, 2017 Intangibles, net: Beginning balance $ 7,207 $ 8,447 Increase — — Amortization (1,250 ) (1,240 ) Ending balance 5,957 7,207 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 9,879 $ 11,129 Warrant Liability Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in the fair value included in net loss until they are either exercised or expire , subject to adjustment, The initial fair value of the liability associated with these warrants was $3.1 million, and the fair value decreased to $0.9 million as of , 2018. The main driver for the change in the fair value of warrants at , 2018, was related to the change in our stock price. The warrants are not traded in an active securities market, and as such the estimated the fair value as of December 31 As of As of (inception date) Expected term 2.1 years 2.5 years Common stock market price $ 0.29 $ 0.72 Risk-free interest rate 2.48% 2.70% Expected volatility 125% 112% Resulting fair value (per warrant) $ 0.13 $ 0.45 Expected volatility was computed using daily pricing observations of traded shares of Cytori for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the U.S. Treasury bond rate as of the valuation date. Fluctuations in the fair value of the warrants are impacted by unobservable inputs, most significantly the assumption with regards to future equity issuances and its impact to the down-round protection feature. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value measurement. Refer to Note 3 for a discussion of the change in our Level 3 warrant liability value. Revenue Recognition Product Sales The Company’s revenue recognition accounting policy until December 31, 2017, prior to the adoption of the new revenue standard We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. The Company’s revenue recognition accounting policy from January 1, 2018, following the adoption of the new revenue standard Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes. The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. The following table represents revenue by product (in thousands): Years ended December 31, 2018 2017 Consumable $ 2,169 $ 1,918 Device 225 576 Other products 277 195 $ 2,671 $ 2,689 Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2018 2017 Product Revenues % of Total Product Revenues % of Total Americas $ 293 11 % $ 345 13 % Japan 2,058 77 % 1,924 71 % EMEA 270 10 % 344 13 % Asia Pacific 50 2 % 76 3 % Total product revenues $ 2,671 100 % $ 2,689 100 % License Revenue For arrangements that include sales-based royalties, including milestone payments based on the level of sales or gross profits, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue based on an assessment of the probability of achievement of the milestones and the likelihood of a significant reversal of such milestone revenue at each reporting date. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. In conjunction with a sale and license agreement with Bimini Technologies LLC in 2013, we agreed on certain contingent milestone consideration upon this licensee’s achievement of certain commercial product milestones. As of December 31, 2018, the Company recognized $1.0 million corresponding to a royalty for commercial milestone achieved. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2018, our sales were concentrated with respect to two direct customers, which comprised 60% of our product revenue recognized. Two direct customers accounted for 70% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2018. For the year ended December 31, 2017, our sales were concentrated with respect to five direct customers, which comprised 68% of our product revenue recognized. One licensee and one direct customer accounted for 77% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2017. Development Revenues The Company earns revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $3.0 million and $3.7 million in BARDA revenue for the years ended December 31, 2018 and 2017, respectively. Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $2.7 million and $3.5 million of qualified expenses that were incurred for the years ended December 31, 2018 and 2017, related to our government contract with BARDA. Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2018 and 2017, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. Segment Information For the years ended December 31, 2018 and 2017, the Company is managed as a single operating segment, therefore we report our results in one operating segment. Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2018 and 2017, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 13.7 million as of December 31, 2018, which includes 8.9 million outstanding warrants and 0.1 million options, 4.7 million of preferred stocks, and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 0.5 million as of December 31, 2017. Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases We will adopt this new standard on January 1, 2019 (the "effective date") using the modified retrospective transition option of applying the new standard at the adoption date. As such, we will not adjust prior period amounts. Furthermore, we expect to elect the practical expedients upon transition, which permit companies to not reassess lease identification, classification, and initial direct costs under the new standard for leases that commenced prior to the effective date. We have substantially completed the process of analyzing and extracting relevant data from the Company’s lease contracts. We are finalizing our evaluation of the impact that this guidance will have on our financial statements, including related disclosures, and expect to recognize additional right-of-use assets and corresponding lease liabilities related to operating leases. In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers cumulative effect of applying the new standards as of the adoption date on In November 2016, the FASB issued ASU 2016-18, Restricted Cash in the first quarter of 2018, . The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the consolidated statements of cash flows includes restricted cash of $0.4 million, $0.7 million, and $40,000 and cash, cash equivalents of $12.6 million, $9.6 million, and $5.3 million as of December 31, 2016, December 31, 2017 and December 31, 2018, respectively.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value	3. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. As of December 31, 2017, we did not have any asset or liability measured at fair value presented on our balance sheet. Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in the fair value included in net loss for the respective periods. Because some of the inputs to our valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy. The following table summarizes the change in our Level 3 warrant liability value (in thousands): Years ended December 31, Warrant liability 2018 2017 Beginning balance $ 3,148 $ — Change in fair value (2,233 ) — Ending balance $ 916 $ — Financial Instruments We disclose fair value information about all financial instruments, whether or not recognized in the balance sheets, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at December 31, 2018 and 2017, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts. The carrying amounts for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value. At December 31, 2018 and 2017, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Debt $ 14,043 $ 14,202 $ 13,427 $ 13,624 Carrying value is net of debt discount of $0.6 million and $0.4 million as of December 31, 2018 and 2017, respectively. The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs, primarily the effective interest rate, to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means. Nonfinancial Assets and Liabilities We apply fair value techniques on a non-recurring basis associated with: (1) valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles—goodwill and other; and (2) valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment.

Asset Purchase Agreement with A

Asset Purchase Agreement with Azaya Therapeutics	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Asset Purchase Agreement with Azaya Therapeutics	4. Asset Purchase Agreement with Azaya Therapeutics On February 15, 2017 (the “Closing Date”), we completed the acquisition from Azaya Therapeutics, Inc. (“Azaya”) of certain tangible assets which consisted of a research lab, equipment and leasehold improvements and the assumption of certain of liabilities of Azaya, pursuant to an Asset Purchase Agreement (the “Agreement”). The book value of the tangible assets acquired was approximately $3.0 million at the acquisition date. The assets acquired are located in a facility rented in San Antonio, TX, by Cytori. In addition, pursuant to the Agreement, we acquired intangible assets comprised of two drug candidates in process research and development (IPR&D) stage (i) ATI-0918, a generic bioequivalent formulation of Doxil ® ® At the closing of the acquisition, we (i) issued 117,325 of shares of our common stock in Azaya’s name, (A) 87,994 of which were delivered to Azaya promptly after the Closing, and (B) 29,331 of which were deposited into a 15-month escrow pursuant to a standard escrow agreement; and (ii) assumed the obligation to pay approximately $1.8 million of Azaya’s existing payables, all of which December In addition, as of the Closing Date, the Company committed to certain contingent consideration to: (i) pay Azaya fixed commercialization milestone payments based upon achievement of certain net sales milestones for ATI-0918; (ii) make certain earn-out payments to Azaya equal to a mid-single-digit percentage of net sales of ATI-0918; and (iii) make certain earn-out payments to Azaya equal to a low single-digit percentage of net sales of any product (ATI-0918 is the “Generic Product” and ATI-1123 is the “Patented Product”), including ATI-1123, that practices a claim in the related patent assigned by Azaya to the Company (the “ATI-1123 Patent”). Our aggregate earn-out payment obligations to Azaya from global net sales of both ATI-0918 and any Patented Product will not exceed $100.0 million (the “Earn-Out Cap”). Further, the Agreement provides that if we enter into certain assignments, licenses or other transfers of rights to a Patented Product or the ATI-1123 Patent, we will pay Azaya a percentage in the low to mid-teens of the consideration received by us, provided, that our aggregate payment obligation to Azaya for any such assignment, license or other transfer of rights will not exceed $50.0 million. If the Company or its successors, sublicenses or transferees sells a competing product to ATI-0918 at any time prior to satisfaction of the Earn-Out Cap, other than because ATI-0918 fails to receive marketing authorization from the European Medicines Agency within a certain period of time or fails to generate a minimum threshold of net sales within a pre-determined amount of time, then 50% of the net sales of such competing product would be deemed to be net sales of ATI-0918 under the Agreement for purposes of calculating commercialization milestone payments and earn-out payments. We accounted for the acquisition as an asset acquisition because the acquired set of assets did not meet the definition of a business. The total consideration of $4.3 million, which consists of $2.3 million related to the fair value of the common stock issued to Azaya at the acquisition date, $1.8 million in assumed liabilities and $0.2 million in acquisition costs, was allocated to the assets acquired based on their relative fair values at the time of acquisition. All other future payments were deemed contingent consideration which will be accounted for when the contingency is resolved and the consideration is paid or becomes payable. When determining the fair value of tangible assets acquired, the Company estimated the cost to replace the tangible asset with a new asset, taking into consideration such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets acquired, the Company used a discounted cash flow model with key inputs being the applicable discount rate, market growth rates and the timing and amount of future cash flows. The acquired IPR&D is in the early stage of development. Additional research, pre-clinical studies, and regulatory approvals must be successfully completed prior to selling any product. Because there is no current alternative use for the IPR&D, following the authoritative accounting guidance, the Company has expensed it in full on the Closing Date. The Company measured the fair value of the shares issued as consideration in the acquisition of the assets based on the stock price at the acquisition date. Transaction costs directly related to the acquisition of the assets have been capitalized. The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Composition of Certain Financia

Composition of Certain Financial Statement Captions	12 Months Ended
	Dec. 31, 2018
Composition Of Certain Financial Statement Captions [Abstract]
Composition of Certain Financial Statement Captions	5. Composition of Certain Financial Statement Captions Inventories, net As of December 31, 2018 and 2017, inventories, net, were comprised of the following (in thousands): December 31, 2018 2017 Raw materials $ 758 $ 681 Work in process 555 722 Finished goods 1,634 1,780 $ 2,947 $ 3,183 Other Current Assets As of December 31, 2018 and 2017, other current assets were comprised of the following (in thousands): December 31, 2018 2017 Prepaid supplies or services, current $ 440 $ 544 Prepaid insurance 564 556 Prepaid consumption tax in Japan 19 99 Other receivables 91 112 $ 1,114 $ 1,311 Property and Equipment, net As of December 31, 2018 and 2017, property and equipment, net, were comprised of the following (in thousands): December 31, 2018 2017 Manufacturing and development equipment $ 3,753 $ 4,507 Office and computer equipment 1,242 1,805 Leasehold improvements 2,535 5,087 7,530 11,399 Less accumulated depreciation (4,971 ) (8,347 ) $ 2,559 $ 3,052 Depreciation expense totaled $0.8 million and $0.9 million for the years ended December 31, 2018 and 2017, respectively. Other Assets As of December 31, 2018 and 2017, other assets were comprised of the following (in thousands): December 31, 2018 2017 Long-term supplies $ 1,540 $ 2,181 Deposits 365 389 $ 1,905 $ 2,570 Accounts Payable and Accrued Expenses As of December 31, 2018 and 2017, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2018 2017 Accrued expenses $ 1,191 $ 1,599 Accounts payable 720 1,297 Accrued payroll and bonus 554 810 Accrued legal fees 186 509 Accrued vacation 192 64 Accrued R&D studies 230 286 Other current liabilities 284 225 $ 3,357 $ 4,790

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December 31, 2018, we have clinical research study obligations of $3.0 million , $1.8 million of which is expected to be paid within a year We lease facilities for our headquarters office location as well as international office locations. As of December 31, 2018, we have contractual lease obligations to make payments on leases of office and manufacturing space as follows: Years Ending December 31, Obligation 2019 $ 1,282 2020 638 2021 638 2022 192 Total $ 2,750 Rent expense, which includes common area maintenance, for the years ended December 31, 2018 and 2017 was $1.9 million and $2.2 million, respectively. On February 27, 2017, we entered into a Lease Agreement of office space for our corporate headquarters in San Diego, California (the “Lease”). The initial term of the Lease is 63 months and may be extended upon mutual agreement. The commencement date was originally expected to take place in November 2017 and subsequently amended to January 1, 2018. In connection with our restructuring announced in September 2017, we began negotiations with the landlord and in February 2018, announced a buy-out of our obligations with the Lease of approximately $0.6 million, included in the general and administrative expenses. On January 27, 2017, we entered into a Lease Agreement of office space for our office in Tokyo, Japan (the “Japan Lease”). The initial term of the Japan Lease is 61 months, and may be extended upon mutual agreement. The Lease commenced on April 15, 2017. We were party to an agreement with Roche Diagnostics Corporation (“Roche”) On June 8, 2018, the Company received written notice from Roche terminating its existing supply agreement with the Company due to failure by the Company to meet minimum purchase requirements. Roche has indicated to the Company that it will agree to negotiate in good faith with the Company with respect to a new supply agreement for enzymes with specifications similar to the enzymes that Roche was previously manufacturing for the Company. We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole. On April 27, 2018, Lorem Vascular (“Lorem”) filed suit against the Company in the U.S. District Court for the Southern District of California alleging the Company breached an oral agreement made in 2013 to purchase 5% of Lorem’s common stock for an aggregate amount of $5.0 million, and seeking specific performance of the alleged oral agreement and damages in an amount to be determined at On August 31, 2018, we filed a Demand for Arbitration with the American Arbitration Association in San Diego, California, against Bimini Technologies LLC (“Bimini”) for fraud and breach of a Sale and Exclusive License/Supply Agreement made in 2013 under which Bimini licensed rights to the Company’s Standalone Fat Transplantation, including the Puregraft Product Line and associated trademarks. Our arbitration demand alleged that Bimini failed to make a $1.0 million milestone payment due to the Company after Bimini achieved $10.0 million in gross profits from the sale of the Company’s Puregraft product line, and Bimini deceived the Company about Bimini’s true gross profits figures. Our arbitration demand sought that $1.0 million milestone payment, as well prejudgment interest and attorneys’ fees. On October 29, 2018 Bimini made the $1.0 million milestone payment. The parties subsequently entered into a settlement agreement resolving the claims in the Demand for Arbitration.

Term Loan Obligations

Term Loan Obligations	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Term Loan Obligations	7. Term Loan Obligations On May 29, 2015, the Company On September 20, 2017, the Company entered into an amendment to the Term Loan, pursuant to which, among other things, Oxford agreed to reduce the minimum liquidity covenant level originally at $5 million to $1.5 million. The amendment also extended the interest-only period under the Loan Agreement through August On June 19, 2018, the Company entered into a second amendment (the “Second Amendment”) to the Term Loan with Oxford. The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018. The Company agreed to pay Oxford an amendment fee of $250,000 at the earlier of maturity or acceleration of the loan. On August 31, 2018, the Company entered into a third amendment (the “Third Amendment”) to the Term Loan with Oxford. The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”). The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid. The Company agreed to pay Oxford an amendment fee of $50,000 at the earlier of maturity or acceleration of the loan. On December 31, 2018, the Company entered into a fourth amendment (the “Fourth Amendment”) to the Term Loan with Oxford. Oxford agreed to extend the maturity date from June 1, 2019 to June 1, 2020. The Amendment increases the minimum liquidity covenant level from $1.5 million to $2.0 million and extends the interest-only period under the Loan Agreement to March 1, 2019. The Amendment also requires that the Company achieve one of the following by January 31, 2019: enter into an asset sale agreement with a minimum unrestricted net cash proceeds to the Company of $4.0 million; enter into a binding agreement for the issuance and sale of its equity securities or unsecured convertible subordinated debt which would result in unrestricted gross cash proceeds of not less than $7.5 million; or enter into a merger agreement pursuant to which the obligations under the Loan Agreement would be paid down to a level satisfactory to Oxford. The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving certain liquidity levels when the total principal outstanding under the Loan Agreement is less than $3 million. , 2018 The Term Loan Agreement contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by us or a declaration of material adverse change by our lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Term Loan, which could materially harm our financial condition. As of December 31 , 2018 Additional details relating to the outstanding Term Loan as of December 31, 2018 and 2017 are presented in the following table (in thousands): Year ended December 31, 2018 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 Year ended December 31, 2017 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 * ** *** As of December 31, 2018, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2019 $ 8,653 2020 6,090 Total $ 14,743 Reconciliation of Face Value to Book Value as of December 31, 2018 Total debt and lease obligations, including final payment fee (Face Value) $ 14,743 Less: Debt discount (541 ) Total obligation $ 14,202 Our interest expense for the years ended December 31, 2018 and 2017 was $1.9 million and $2.0 million, respectively. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $0.6 million and $0.7 million, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes Due to our net losses for the years ended December 31, 2018 and 2017, and since the Company has recorded a full valuation allowance against deferred tax assets, there was no provision or benefit for income taxes recorded. The components of income/(loss) before income tax provision (benefit) as of December 31, 2018 and 2017 are as follows (in thousands): 2018 2017 U.S. $ (12,240) $ (21,915) Foreign (394) (771) $ (12,634) $ (22,686) A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% and 34% for the years ended December 31, 2018 and 2017, respectively, is as follows: 2018 2017 Income tax expense (benefit) at federal statutory rate (21.0 )% (34.0 )% Income tax expense (benefit) at state statutory rate (5.8 )% (3.9 )% Change in valuation allowance 31.8 % (172.4 )% Change in state rate (0.1 )% (0.8 )% Permanent interest adjustments 0.5 % 0.2 % Stock compensation 1.3 % 3.0 % Research credit (1.0 )% (1.1 )% Foreign rate differential — 202.1 % NOLs expiring and adjustments to NOL — 7.0 % Mark to market adjustment (3.7 )% — Other, net (2.0 )% (0.1 )% 0.0 % 0.0 % The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2018 and 2017 are as follows (in thousands): 2018 2017 Deferred tax assets: Allowances and reserves $ 270 $ 140 Accrued expenses 122 154 Stock based compensation 996 1,065 Net operating loss carryforwards 91,197 87,426 Income tax credit carryforwards 8,671 8,587 Property and equipment, principally due to differences in depreciation 548 514 Other, net 38 45 101,842 97,931 Valuation allowance (101,091 ) (97,089 ) Total deferred tax assets, net of allowance 751 842 Deferred tax liabilities: Intangibles assets (751 ) (842 ) Total deferred tax liability (751 ) (842 ) Net deferred tax assets (liability) $ — $ — The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluate the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $101.1 million as of December 31, 2018 as it does not believe it is more likely than not our net deferred tax assets will be realized. The Company increased its valuation allowance by approximately $4.0 million during the year ended December 31, 2018. At December 31, 2018, we had federal, and state tax loss carry forwards of approximately $380.6 million, and $156.8 million, respectively. The federal and state net operating loss carry forwards begin to expire in 2019 and 2028, respectively, if unused. The federal net operating loss carryover includes $13.1 million of net operating losses generated in 2018. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. At December 31, 2018, we had federal and state tax credit carry forwards of approximately $5.2 million and $4.5 million, respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2019, if unused, and the state credits carry forward indefinitely. Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC §382 and IRC §383, The Company’s ability to use net operating loss and R&D tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382 for taxable years ended after December 31, 2007. If ownership changes within the meaning of IRC Section 382 are identified as having occurred subsequent to 2007, the amount of remaining tax attribute carry forwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC §382. In December 2017, the Tax Cuts and Jobs Act (the "2017 Act) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. In 2017 and in the first nine months of 2018, the Company recorded provisional amounts for certain enactment-date effects of the act by applying the guidance in Staff Accounting Bulletin No. 118 ("SAB 118") because we had not completed our accounting for these effects. In 2018 and 2017, the Company recorded $0 net tax expense related to the enactment-date effects of the Act related to the remeasurement of deferred tax assets and liabilities. There were no changes made in 2018 to our 2017 enactment-date provisional amounts. The Company applied the guidance in SAB 118 when accounting for the enactment-date effects of the Act in 2017 and throughout 2018. At December 31, 2017, the Company had not completed its accounting for all of the enactment-date income tax effects of the Act under ASC 740, Income Taxes, related to the remeasurement of deferred tax assets and liabilities. At December 31, 2018, the Company has now completed our accounting for all of the enactment-date income tax effects of the Act and no adjustments were made to the provisional amounts recorded at December 31, 2017. As of December 31, 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they were expected to reverse in the future (which was generally 21%), by recording a provisional amount of $45.8 million, which was fully offset by valuation allowance. Upon further analysis of certain aspects of the Act and refinement of our calculations during the 12 months ended December 31, 2018, the Company determined that no adjustment was necessary to our provisional amount. The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax positions as of December 31, 2018 and 2017. Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2018 and 2017 (in thousands): 2018 2017 Unrecognized Tax Benefits – Beginning $ 2,157 $ 2,062 Gross increases – tax positions in prior period 1 — Gross decreases – tax positions in prior period (3 ) — Gross increase – current-period tax positions 61 95 Unrecognized Tax Benefits – Ending $ 2,216 $ 2,157 The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. The Company did not recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses as of December 31, 2018. The Company’s material tax jurisdictions are United States and California. To its knowledge, the Company is currently not under examination by the Internal Revenue Service or any other taxing authority. The Company’s tax years for 1998 (federal) and 1997 (CA) and forward can be subject to examination by the United States and California tax authorities due to the carry forward of net operating losses and research development credits.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	9. Employee Benefit Plan We implemented a 401(k) retirement savings and profit sharing plan (the “Plan”) effective January 1, 1999. We may make discretionary annual contributions to the Plan, which is allocated to the profit sharing accounts based on the number of years of employee service and compensation. At the sole discretion of the Board of Directors, we may also match the participants’ contributions to the Plan. We made no discretionary or matching contributions to the Plan in 2018 or 2017.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders Equity Note [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock and 10,000 Series B Preferred Stock On November 27, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the “Series B Convertible Preferred Stock”. The number of shares initially constituting the Series B Convertible Preferred Stock was set at 10,000 shares. Pursuant to a registration statement on Form S-1, originally filed on August 14, 2017, as amended, and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on November 2, 2017, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 10,000 units consisting of 10,000 shares of Series B Convertible Preferred Stock and 18 million warrants, with every 10 warrants exercisable for one common stock at an exercise price of $3.333 per share for 30 months from the date of issuance at any time after the date the stockholder approval to increase our authorized common stock share count. Pursuant to the 2017 Rights Offering, which closed on November 28, 2017, the Company sold an aggregate of 10,000 units, resulting in total net proceeds to the Company of approximately $8.8 million. Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $8.33 per share for 10 consecutive trading days. On July 25, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Certificate of Designation”) with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The number of shares initially constituting the Series C Preferred Stock was set at 7,000 shares. Pursuant to a registration statement on Form S-1 originally filed on April 27, 2018, as amended, and became effective on July 17, 2018, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock and Series B Convertible Preferred Stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 20,000 units each consisting of one share of Series C Preferred Stock and 1,050 warrants for $1,000 per unit. Each warrant is exercisable for one share of the Company’s common stock at an exercise price of $0.7986 per share for 30 months from the date of issuance and each share of Series C Preferred Stock is convertible into 1,253 shares of the Company's common stock. Pursuant to the 2018 Rights Offering, which closed on July 25, 2018, the Company sold an aggregate of 6,723 units, resulting in total net proceeds to the Company of approximately $5.7 million. The fair value of the common stock into which the Series C Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a deemed dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. We recorded a deemed dividend within additional paid-in capital of $2.5 million for the quarter ended December 31, 2018, related to a beneficial conversion feature included in the issuance of our Series C Convertible Preferred Stock. Common Stock On April 11, 2017, we entered into the Underwriting Agreement with Maxim relating to the issuance and sale of 0.9 million shares of our common stock. The price to the public in the offering was $11.00 per share. Maxim purchased the shares from us pursuant to the Underwriting Agreement at a price of $10.40 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed . In addition, under the terms of the Underwriting Agreement, we granted Maxim a 45-day overallotment option to purchase up to 94,400 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 84,900 shares at $11.00 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us. On June 1, 2018, the Company entered into a Sales Agreement with B. Riley FBR to sell shares of its common stock having an aggregate offering price of up to $6.5 million through its ATM program. Through December 31, 2018, the Company sold a total of 3.9 million shares for proceeds of approximately $1.7 million through the ATM program. On September 21, 2018, the Company entered into a Purchase Agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $5.0 million of shares, of the Company’s common stock, over the 24-month period following October 15, 2018. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 250,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. The Company’s sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of no more than 4.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event under an accelerated purchase will shares be sold to Lincoln Park on a day the closing price of the Company’s common stock is less than the floor price of $0.25 per share as set forth in the Lincoln Park Purchase Agreement. Through December 31, 2018, the Company sold a total of 0.6 million shares for proceeds of approximately $0.3 million through the Lincoln Park Purchase Agreement

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	11. Stock-based Compensation In August 2014, we adopted the 2014 Equity Incentive Plan (the “2014 Plan”), which provides our employees, directors and consultants the opportunity to purchase our common stock in the form of options (incentive or non-qualified), stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards other stock-based awards, and deferred compensation awards. The 2014 Plan initially provides for issuance of 26,500 shares of our common stock. In August 2015, the Company amended the 2014 Plan to add 30,180 shares to its share pool. In addition, the amendment increased the number of “incentive stock options” which may be issued under the 2014 Plan by an identical amount. In May 2016, May 2017 and May 2018, the Company amended the 2014 Plan to add 33,333, 200,000, and 750,000 shares, respectively, to its share pool. On December 29, 2015, we adopted the 2015 New Employee Incentive Plan (the “2015 Plan”). Awards under the 2015 Plan may only be made to an employee who has not previously been an employee or member of the Board of any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The 2015 Plan provides for issuance of 6,666 shares. In January 2017, the Company amended the 2015 Plan to add 25,000 shares to its share pool. As of December 31, 2018, there are 171 shares and 947,856 shares of common stock remaining and available for future issuances under the 2015 and 2014 Plans, respectively, which are exclusive of securities to be issued upon an exercise of outstanding options, warrants, and rights. Stock Options Generally, options issued under the 2014 Plan, are subject to four-year vesting, and have a contractual term of 10 years. Most options contain one of the following two vesting provisions: • 12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or • 1/48 of the award will vest at the end of each month over a four-year period. A summary of activity for the year ended December 31, 2018 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2018 100,870 $ 119.25 Granted 117,300 $ 2.16 Expired (1,033 ) $ 771.07 Cancelled/forfeited (79,590 ) $ 5.93 Balance as of December 31, 2018 137,547 $ 80.07 Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2018 137,547 $ 80.07 7.90 $ — Vested and expected to vest at December 31, 2018 122,637 $ 88.94 7.78 $ — Exercisable at December 31, 2018 64,836 $ 161.99 6.59 $ — There were no stock options exercised in 2018 or 2017. The fair value of each option awarded during the year ended December 31, 2018 and 2017 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2018 2017 Expected term 7.1 years 6.6 years Risk-free interest rate 2.94 % 2.20 % Volatility 92.87 % 78.84 % Dividends — — Resulting weighted average grant date fair value $ 1.74 $ 1.05 The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, we use the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. The dividend yield has been assumed to be zero as we (a) have never declared or paid any dividends and (b) do not currently anticipate paying any cash dividends on our outstanding shares of common stock in the foreseeable future. Restricted Stock Awards Generally, restricted stock awards issued under the 2014 Plan are subject to a vesting period that coincides with the fulfillment of service requirements for each award and have a contractual term of 10 years. These awards are amortized to compensation expense over the estimated vesting period based upon the fair value of our common stock on the award date. The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2018 2017 Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) $ 355 $ 753 As of December 31, 2018, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is approximately $0.2 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.5 years. To settle stock options and restricted stock awards, we will issue new shares of our common stock. At December 31, 2018, we have an aggregate of 1,005,706 shares authorized and available to satisfy option exercises under our plans.

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2018
Valuation And Qualifying Accounts [Abstract]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	For the years ended December 31, 2018 and 2017 (in thousands) Balance at beginning of year Additions (A) Deductions (B) Other (C) Balance at end of year Allowance for doubtful accounts Year ended December 31, 2018 $ 167 $ 18 $ — $ — $ 185 Year ended December 31, 2017 $ 167 $ — $ — $ — $ 167 (A) Includes charges to costs and expenses. (B) Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers. (C) Miscellaneous activity.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, valuing warrants, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Cash and cash equivalents	Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2018 and 2017. We maintain our cash at insured financial institutions.
Restricted Cash	Restricted Cash Restricted cash consists of cash invested in certificate of deposits used as collateral for the issuance of letters of credit pursuant to lease agreements for leasing of property at 3020 and 3030 Callan Road, San Diego, CA, which requires us to execute a letter of credit for $40,000 and $0.7 million naming the landlord as a beneficiary as of December 31, 2018 and 2017, respectively.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventories	Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or net realizable value. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred.
Impairment	Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements.
Goodwill and Intangibles	Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. We experienced significant volatility in our share price during the year. During Q3 2018 and Q4 2018, our stock price significantly declined in comparison to the corresponding previous quarters. We performed a valuation of our single reporting unit as of September 30, 2018 (and as updated for the annual test during the fourth quarter in 2018). Based upon the results of our valuation, management concluded that the fair value of the reporting unit exceeded its carrying value. We determined that a blending of the income approach and an option pricing model back-solve was a reasonable approximation of the fair value of the reporting unit. Additionally, a further reduction in our market capitalization could be an indicator of impairment. Given the volatility of our stock price a continued decline in market capitalization could result in an impairment of our goodwill. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture with Olympus Corporation, we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2018 and 2017 are as follows (in thousands): December 31, 2018 December 31, 2017 Intangibles, net: Beginning balance $ 7,207 $ 8,447 Increase — — Amortization (1,250 ) (1,240 ) Ending balance 5,957 7,207 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 9,879 $ 11,129
Warrant Liability	Warrant Liability Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in the fair value included in net loss until they are either exercised or expire , subject to adjustment, The initial fair value of the liability associated with these warrants was $3.1 million, and the fair value decreased to $0.9 million as of , 2018. The main driver for the change in the fair value of warrants at , 2018, was related to the change in our stock price. The warrants are not traded in an active securities market, and as such the estimated the fair value as of December 31 As of As of (inception date) Expected term 2.1 years 2.5 years Common stock market price $ 0.29 $ 0.72 Risk-free interest rate 2.48% 2.70% Expected volatility 125% 112% Resulting fair value (per warrant) $ 0.13 $ 0.45 Expected volatility was computed using daily pricing observations of traded shares of Cytori for recent periods that correspond to the expected term of the warrants. We believe this method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants. We currently have no reason to believe future volatility over the expected remaining life of these warrants is likely to differ materially from historical volatility. The expected life is based on the remaining contractual term of the warrants. The risk-free interest rate is the U.S. Treasury bond rate as of the valuation date. Fluctuations in the fair value of the warrants are impacted by unobservable inputs, most significantly the assumption with regards to future equity issuances and its impact to the down-round protection feature. Significant increases (decreases) in this input in isolation would result in a significantly higher (lower) fair value measurement. Refer to Note 3 for a discussion of the change in our Level 3 warrant liability value.
Revenue Recognition	Revenue Recognition Product Sales The Company’s revenue recognition accounting policy until December 31, 2017, prior to the adoption of the new revenue standard We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. The Company’s revenue recognition accounting policy from January 1, 2018, following the adoption of the new revenue standard Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes. The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. The following table represents revenue by product (in thousands): Years ended December 31, 2018 2017 Consumable $ 2,169 $ 1,918 Device 225 576 Other products 277 195 $ 2,671 $ 2,689 Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2018 2017 Product Revenues % of Total Product Revenues % of Total Americas $ 293 11 % $ 345 13 % Japan 2,058 77 % 1,924 71 % EMEA 270 10 % 344 13 % Asia Pacific 50 2 % 76 3 % Total product revenues $ 2,671 100 % $ 2,689 100 % License Revenue For arrangements that include sales-based royalties, including milestone payments based on the level of sales or gross profits, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue based on an assessment of the probability of achievement of the milestones and the likelihood of a significant reversal of such milestone revenue at each reporting date. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. In conjunction with a sale and license agreement with Bimini Technologies LLC in 2013, we agreed on certain contingent milestone consideration upon this licensee’s achievement of certain commercial product milestones. As of December 31, 2018, the Company recognized $1.0 million corresponding to a royalty for commercial milestone achieved. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2018, our sales were concentrated with respect to two direct customers, which comprised 60% of our product revenue recognized. Two direct customers accounted for 70% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2018. For the year ended December 31, 2017, our sales were concentrated with respect to five direct customers, which comprised 68% of our product revenue recognized. One licensee and one direct customer accounted for 77% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2017. Development Revenues The Company earns revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $3.0 million and $3.7 million in BARDA revenue for the years ended December 31, 2018 and 2017, respectively.
Research and Development	Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $2.7 million and $3.5 million of qualified expenses that were incurred for the years ended December 31, 2018 and 2017, related to our government contract with BARDA.
Deferred Financing Costs and Other Debt-Related Costs	Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2018 and 2017, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months.
Share-Based Compensation	Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term.
Segment Information	Segment Information For the years ended December 31, 2018 and 2017, the Company is managed as a single operating segment, therefore we report our results in one operating segment.
Loss Per Share	Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2018 and 2017, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 13.7 million as of December 31, 2018, which includes 8.9 million outstanding warrants and 0.1 million options, 4.7 million of preferred stocks, and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 0.5 million as of December 31, 2017.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases We will adopt this new standard on January 1, 2019 (the "effective date") using the modified retrospective transition option of applying the new standard at the adoption date. As such, we will not adjust prior period amounts. Furthermore, we expect to elect the practical expedients upon transition, which permit companies to not reassess lease identification, classification, and initial direct costs under the new standard for leases that commenced prior to the effective date. We have substantially completed the process of analyzing and extracting relevant data from the Company’s lease contracts. We are finalizing our evaluation of the impact that this guidance will have on our financial statements, including related disclosures, and expect to recognize additional right-of-use assets and corresponding lease liabilities related to operating leases. In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers cumulative effect of applying the new standards as of the adoption date on In November 2016, the FASB issued ASU 2016-18, Restricted Cash in the first quarter of 2018, . The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the consolidated statements of cash flows includes restricted cash of $0.4 million, $0.7 million, and $40,000 and cash, cash equivalents of $12.6 million, $9.6 million, and $5.3 million as of December 31, 2016, December 31, 2017 and December 31, 2018, respectively.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Intangible Assets and Goodwill	The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2018 and 2017 are as follows (in thousands): December 31, 2018 December 31, 2017 Intangibles, net: Beginning balance $ 7,207 $ 8,447 Increase — — Amortization (1,250 ) (1,240 ) Ending balance 5,957 7,207 Goodwill, net: Beginning balance 3,922 3,922 Increase (decrease) — — Ending balance 3,922 3,922 Total goodwill and other intangibles, net $ 9,879 $ 11,129
Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions	The warrants are not traded in an active securities market, and as such the estimated the fair value as of December 31 As of As of (inception date) Expected term 2.1 years 2.5 years Common stock market price $ 0.29 $ 0.72 Risk-free interest rate 2.48% 2.70% Expected volatility 125% 112% Resulting fair value (per warrant) $ 0.13 $ 0.45
Revenue by Product	The following table represents revenue by product (in thousands): Years ended December 31, 2018 2017 Consumable $ 2,169 $ 1,918 Device 225 576 Other products 277 195 $ 2,671 $ 2,689
Product Revenues, Classified by Geographic Location	Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2018 2017 Product Revenues % of Total Product Revenues % of Total Americas $ 293 11 % $ 345 13 % Japan 2,058 77 % 1,924 71 % EMEA 270 10 % 344 13 % Asia Pacific 50 2 % 76 3 % Total product revenues $ 2,671 100 % $ 2,689 100 %

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Change in Level 3 Warrant Liability Value	The following table summarizes the change in our Level 3 warrant liability value (in thousands): Years ended December 31, Warrant liability 2018 2017 Beginning balance $ 3,148 $ — Change in fair value (2,233 ) — Ending balance $ 916 $ —
Fair Value and Carrying Value of Long-term Debt	At December 31, 2018 and 2017, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2018 December 31, 2017 Fair Value Carrying Value Fair Value Carrying Value Debt $ 14,043 $ 14,202 $ 13,427 $ 13,624

Asset Purchase Agreement with_2

Asset Purchase Agreement with Azaya Therapeutics (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Summery Of Purchase Price Allocation On Fair Value Basis To Identifiable Net Assets	The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Composition of Certain Financ_2

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2018
Composition Of Certain Financial Statement Captions [Abstract]
Inventories, net	Inventories, net As of December 31, 2018 and 2017, inventories, net, were comprised of the following (in thousands): December 31, 2018 2017 Raw materials $ 758 $ 681 Work in process 555 722 Finished goods 1,634 1,780 $ 2,947 $ 3,183
Other Current Assets	Other Current Assets As of December 31, 2018 and 2017, other current assets were comprised of the following (in thousands): December 31, 2018 2017 Prepaid supplies or services, current $ 440 $ 544 Prepaid insurance 564 556 Prepaid consumption tax in Japan 19 99 Other receivables 91 112 $ 1,114 $ 1,311
Property and Equipment, net	Property and Equipment, net As of December 31, 2018 and 2017, property and equipment, net, were comprised of the following (in thousands): December 31, 2018 2017 Manufacturing and development equipment $ 3,753 $ 4,507 Office and computer equipment 1,242 1,805 Leasehold improvements 2,535 5,087 7,530 11,399 Less accumulated depreciation (4,971 ) (8,347 ) $ 2,559 $ 3,052
Other Assets	Other Assets As of December 31, 2018 and 2017, other assets were comprised of the following (in thousands): December 31, 2018 2017 Long-term supplies $ 1,540 $ 2,181 Deposits 365 389 $ 1,905 $ 2,570
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses As of December 31, 2018 and 2017, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2018 2017 Accrued expenses $ 1,191 $ 1,599 Accounts payable 720 1,297 Accrued payroll and bonus 554 810 Accrued legal fees 186 509 Accrued vacation 192 64 Accrued R&D studies 230 286 Other current liabilities 284 225 $ 3,357 $ 4,790

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Future Minimum Debt and Lease Payments	As of December 31, 2018, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2019 $ 8,653 2020 6,090 Total $ 14,743
Payment on Lease Office and Manufacturing Space [Member]
Future Minimum Debt and Lease Payments	As of December 31, 2018, we have contractual lease obligations to make payments on leases of office and manufacturing space as follows: Years Ending December 31, Obligation 2019 $ 1,282 2020 638 2021 638 2022 192 Total $ 2,750

Term Loan Obligations (Tables)

Term Loan Obligations (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Term Loan Outstanding	Additional details relating to the outstanding Term Loan as of December 31, 2018 and 2017 are presented in the following table (in thousands): Year ended December 31, 2018 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 Year ended December 31, 2017 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 100 48 Months $ 12,980 * ** ***
Future Minimum Debt and Lease Payments	As of December 31, 2018, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2019 $ 8,653 2020 6,090 Total $ 14,743
Face Value to Book Value Reconciliation	Reconciliation of Face Value to Book Value as of December 31, 2018 Total debt and lease obligations, including final payment fee (Face Value) $ 14,743 Less: Debt discount (541 ) Total obligation $ 14,202

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Components of Income/(Loss) Before Income Tax Provision (Benefit)	The components of income/(loss) before income tax provision (benefit) as of December 31, 2018 and 2017 are as follows (in thousands): 2018 2017 U.S. $ (12,240) $ (21,915) Foreign (394) (771) $ (12,634) $ (22,686)
Reconciliation of Total Income Tax Provision	A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% and 34% for the years ended December 31, 2018 and 2017, respectively, is as follows: 2018 2017 Income tax expense (benefit) at federal statutory rate (21.0 )% (34.0 )% Income tax expense (benefit) at state statutory rate (5.8 )% (3.9 )% Change in valuation allowance 31.8 % (172.4 )% Change in state rate (0.1 )% (0.8 )% Permanent interest adjustments 0.5 % 0.2 % Stock compensation 1.3 % 3.0 % Research credit (1.0 )% (1.1 )% Foreign rate differential — 202.1 % NOLs expiring and adjustments to NOL — 7.0 % Mark to market adjustment (3.7 )% — Other, net (2.0 )% (0.1 )% 0.0 % 0.0 %
Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2018 and 2017 are as follows (in thousands): 2018 2017 Deferred tax assets: Allowances and reserves $ 270 $ 140 Accrued expenses 122 154 Stock based compensation 996 1,065 Net operating loss carryforwards 91,197 87,426 Income tax credit carryforwards 8,671 8,587 Property and equipment, principally due to differences in depreciation 548 514 Other, net 38 45 101,842 97,931 Valuation allowance (101,091 ) (97,089 ) Total deferred tax assets, net of allowance 751 842 Deferred tax liabilities: Intangibles assets (751 ) (842 ) Total deferred tax liability (751 ) (842 ) Net deferred tax assets (liability) $ — $ —
Unrecognized Tax Benefits Activity	Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2018 and 2017 (in thousands): 2018 2017 Unrecognized Tax Benefits – Beginning $ 2,157 $ 2,062 Gross increases – tax positions in prior period 1 — Gross decreases – tax positions in prior period (3 ) — Gross increase – current-period tax positions 61 95 Unrecognized Tax Benefits – Ending $ 2,216 $ 2,157

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	A summary of activity for the year ended December 31, 2018 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2018 100,870 $ 119.25 Granted 117,300 $ 2.16 Expired (1,033 ) $ 771.07 Cancelled/forfeited (79,590 ) $ 5.93 Balance as of December 31, 2018 137,547 $ 80.07
Stock Options Vested and Expected to Vest	Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2018 137,547 $ 80.07 7.90 $ — Vested and expected to vest at December 31, 2018 122,637 $ 88.94 7.78 $ — Exercisable at December 31, 2018 64,836 $ 161.99 6.59 $ —
Weighted-average Assumptions	The fair value of each option awarded during the year ended December 31, 2018 and 2017 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2018 2017 Expected term 7.1 years 6.6 years Risk-free interest rate 2.94 % 2.20 % Volatility 92.87 % 78.84 % Dividends — — Resulting weighted average grant date fair value $ 1.74 $ 1.05
Compensation Cost Recognized for Stock Options and Restricted Stock Awards	The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2018 2017 Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) $ 355 $ 753

Organization and Operations - A

Organization and Operations - Additional Information (Details)	Sep. 21, 2018USD ($)	Aug. 28, 2018$ / shares	Jul. 25, 2018USD ($)$ / sharesshares	Jun. 01, 2018USD ($)	May 23, 2018$ / sharesshares	Nov. 28, 2017USD ($)$ / sharesshares	Sep. 05, 2017$ / shares	May 31, 2017USD ($)$ / sharesshares	Apr. 11, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)Subsidiary$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	May 24, 2018shares	Nov. 27, 2017shares	Dec. 31, 2016USD ($)shares
Basis Of Presentation And New Accounting Standards [Line Items]
Number of wholly-owned subsidiaries | Subsidiary												5
Reverse stock split of common stock					0.1
Common stock, par value (in dollars per share) | $ / shares					$ 0.001					$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)					75,000,000					100,000,000	100,000,000	100,000,000	100,000,000	100,000,000
Common stock, shares issued (in shares)					61,600,000					14,830,414	14,830,414	14,830,414	14,830,414	6,200,000
Common stock, shares outstanding (in shares)					61,600,000					5,782,573	5,782,573	5,782,573	5,782,573	6,200,000
Number of shares callable by warrants (in shares)					23,400,000									2,300,000
Preferred stock, shares authorized (in shares)					5,000,000					5,000,000	5,000,000	5,000,000	5,000,000	5,000,000
Common stock, reverse stock split, fractional shares issued					0
Net loss | $												$ 12,634,000	$ 22,686,000
Accumulated deficit | $										$ (414,383,000)	$ (414,383,000)	(414,383,000)	(401,749,000)
Net cash used in operating activities | $												$ (11,975,000)	(18,128,000)
Substantial doubt about going concern, description												These factors raise substantial doubt about the Company’s ability to continue as a going concern.
Net proceeds excess receives from unrestricted cash | $												$ 4,000,000
Cash and cash equivalents | $										5,261,000	5,261,000	5,261,000	9,550,000			$ 12,600,000
Minimum cash/cash equivalents covenant | $										$ 2,000,000	$ 2,000,000	2,000,000
Common stock issued (in shares)			6,723			10,000
Proceeds from issuance warrants | $			$ 5,700,000			$ 8,800,000
Date from which warrants are exercisable						May 18, 2018
Common stock issued, value | $												1,624,000	12,716,000
Series B Convertible Preferred Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)						18,000,000
Preferred stock, shares authorized (in shares)															10,000
Common stock issued (in shares)						3,000,000
Common stock issued, value | $													$ 8,767,000
Series C Convertible Preferred Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)			7,059,150
Preferred stock, shares authorized (in shares)			7,000
Number of convertible shares converted into common stock (in shares)			8,400,000
Common stock issued, value | $												$ 3,041,000
Nasdaq Stock Market LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of consecutive business days no longer able to meet the required closing bid price of common stock		30 days					30 days
Minimum bid price of common stock required for Nasdaq listing rule | $ / shares		$ 1					$ 1
Grace period provided with minimum bid price for Nasdaq listing rule		180 days					180 days
Grace date for minimum bid price requirement for Nasdaq listing		Feb. 25, 2019					Mar. 5, 2018
Common stock minimum bid price required to regain compliance | $ / shares		$ 1					$ 1
Number of consecutive business days required to regain compliance		10 days					10 days
Additional grace period provided with minimum bid price to regain compliance		180 days					180 days
Date to regain compliance after meeting continued listing requirement		Aug. 26, 2019					Sep. 4, 2018
Description of compliance with minimum bid price requirement												We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.
Common Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock, shares outstanding (in shares)										14,830,414	14,830,414	14,830,414	5,782,573			2,170,789
Number of shares callable by warrants (in shares)			1			1,800,000
Common stock issued (in shares)			6,723			10,000						4,608,453	1,223,708
Share issued, price per share | $ / shares									$ 11
Warrant exercise price (in dollars per share) | $ / shares			$ 0.7986			$ 3.333
Common stock issued, value | $												$ 5,000	$ 1,000
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock issued (in shares)											3,900,000
Proceeds from sale of common stock, net | $											$ 1,700,000
Common Stock [Member] | Lincoln Park [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Proceeds from sale of common stock, net | $										$ 300,000
Common stock issued, value | $	$ 5,000,000									600,000
Period exercisable from the date of issuance	24 months
Common Stock [Member] | Series B Convertible Preferred Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of convertible shares converted into common stock (in shares)												396,045	2,270,632
Common Stock [Member] | Series C Convertible Preferred Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of convertible shares converted into common stock (in shares)												4,043,343
Common Stock [Member] | Maxim Group LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock issued (in shares)								84,900	900,000
Share issued, price per share | $ / shares								$ 11	$ 10.40
Proceeds from sale of common stock, net | $								$ 800,000	$ 8,700,000
Closing of offering date									Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter									45 days
Additional shares of common stock									94,400
Minimum [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Unrestricted cash and cash equivalents | $										$ 2,000,000	$ 2,000,000	$ 2,000,000
Maximum [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Unrestricted gross cash proceeds required to extend interest-only period | $												$ 7,500,000
Maximum [Member] | Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Proceeds from sale of common stock, net | $				$ 6,500,000
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)					9,100,000									900,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, shares in Millions	1 Months Ended	12 Months Ended
	May 31, 2013	Dec. 31, 2018USD ($)ObligationCustomerSegment$ / sharesshares	Dec. 31, 2017USD ($)CustomerLicenseeSegmentshares	Dec. 31, 2016USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents investments with original maturities		$ 0	$ 0
Impairment loss		0	0
Acquired technology intangible assets		9,400,000
Useful life (in years)	11 years
Amortization expense		1,250,000	1,240,000
2019		1,200,000
2020		1,200,000
2021		1,200,000
2022		1,200,000
Thereafter		900,000
Accumulated amortization on intangible assets		$ 5,900,000	4,700,000
Number of performance obligation | Obligation		1
Payment terms with customers		The Company’s contracts do not involve financing elements as payment terms with customers are less than one year.
Revenue recognized		$ 3,671,000	2,689,000
Qualifying expenditures related to research		2,700,000	3,500,000
Interest or penalties related to income tax matters		$ 0	$ 0
Number of operating segment | Segment		1	1
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		13.7	0.5
Restricted cash		$ 40,000	$ 675,000	$ 400,000
Cash, cash equivalents		$ 5,261,000	$ 9,550,000	$ 12,600,000
Outstanding Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		8.9
Options and Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		0.1
Preferred Stock and Restricted Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares		4.7
Customer Concentration Risk [Member] | Product Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer		2	5
Concentration risk percentage		60.00%	68.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer		2	1
Concentration risk percentage		70.00%	77.00%
Number of licensee | Licensee			1
Royalty [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized		$ 1,000,000
Development [Member] | BARDA Contract [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized		$ 3,000,000	$ 3,700,000
2018 Rights Offering [Member]
Summary Of Significant Accounting Policies [Line Items]
Redemption price of warrant prior to expiration | $ / shares		$ 0.01
Common stock price per share for warrant redemption | $ / shares		$ 3.63
Number of consecutive trading days for warrant redemption		20 days
Warrants liability fair value		$ 900,000	3,100,000
Clinical Technology [Member]
Summary Of Significant Accounting Policies [Line Items]
Amortization expense		$ 1,200,000	1,200,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets		5 years
Letter of Credit [Member]
Summary Of Significant Accounting Policies [Line Items]
Letters of credit amount pursuant to lease agreement		$ 40,000	$ 700,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Intangibles, net:
Intangibles, net, Beginning balance	$ 7,207	$ 8,447
Intangibles, net, Amortization	(1,250)	(1,240)
Intangibles, net, Ending balance	5,957	7,207
Goodwill, net, Beginning balance	3,922	3,922
Goodwill, net Ending balance	3,922	3,922
Total goodwill and other intangibles, net	$ 9,879	$ 11,129

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Fair Value Determined Using Option Pricing Model Assumptions (Details)	Dec. 31, 2018$ / shares	Jul. 25, 2018$ / shares
Expected Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants expected term	2 years 1 month 6 days	2 years 6 months
Common Stock Market Price [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants measurement input	0.29	0.72
Risk-free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants measurement input	0.0248	0.0270
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants measurement input	1.25	1.12
Resulting Fair Value (Per Warrant) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants measurement input	0.13	0.45

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Revenue by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Revenues	$ 3,671	$ 2,689
Consumable [Member]
Concentration Risk [Line Items]
Revenues	2,169	1,918
Device [Member]
Concentration Risk [Line Items]
Revenues	225	576
Other Products [Member]
Concentration Risk [Line Items]
Revenues	277	195
Product [Member]
Concentration Risk [Line Items]
Revenues	$ 2,671	$ 2,689

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Revenues	$ 3,671	$ 2,689
Product [Member]
Concentration Risk [Line Items]
Revenues	$ 2,671	$ 2,689
Concentration risk percentage	100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues	$ 293	$ 345
Concentration risk percentage	11.00%	13.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues	$ 2,058	$ 1,924
Concentration risk percentage	77.00%	71.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues	$ 270	$ 344
Concentration risk percentage	10.00%	13.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues	$ 50	$ 76
Concentration risk percentage	2.00%	3.00%

Fair Value - Summary of Change

Fair Value - Summary of Change in Level 3 Warrant Liability Value (Details) - Warrant Liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Warrant liability
Beginning balance	$ 3,148
Change in fair value	(2,233)
Ending balance	$ 916

Fair Value - Fair Value and Car

Fair Value - Fair Value and Carrying Value of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 14,043	$ 13,427
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 14,202	$ 13,624

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt discount	$ 0.6	$ 0.4

Asset Purchase Agreement with_3

Asset Purchase Agreement with Azaya Therapeutics - Additional Information (Details) - Assets Purchased from Azaya Therapeutics, Inc. [Member]	Feb. 15, 2017USD ($)CandidateEmployeeshares	Dec. 31, 2017USD ($)
Business Acquisition [Line Items]
Obligation to pay on existing payables assumed	$ 1,796,000
Total consideration	4,272,000
Fair value of the common stock issued	2,311,000
Assumed liabilities	1,800,000
Acquisition costs	200,000
Asset Purchase Agreement
Business Acquisition [Line Items]
Book value of tangible assets acquired	$ 3,000,000
Common stock, shares issued | shares	117,325
Common stock, shares issued after closing date | shares	87,994
Common stock deposited in escrow | shares	29,331
Obligation to pay on existing payables assumed	$ 1,800,000
Existing payables, paid during the period		$ 1,800,000
Number of employees | Employee	0
Maximum earn-out payment obligations	$ 100,000,000
Aggregate payment obligation threshold limit	$ 50,000,000
Percentage of net sales deemed for purposes of calculating payments	50.00%
Asset Purchase Agreement | IPR&D [Member]
Business Acquisition [Line Items]
Number of drug candidates acquired | Candidate	2

Asset Purchase Agreement with_4

Asset Purchase Agreement with Azaya Therapeutics - Summery of Purchase Price Allocation on Fair Value Basis to Identifiable Net Assets (Details) - Assets Purchased from Azaya Therapeutics, Inc. [Member] $ in Thousands	Feb. 15, 2017USD ($)
Business Acquisition [Line Items]
Tangible assets	$ 2,586
Intangible assets	1,686
Total assets	4,272
Accounts payable	1,796
Fair value of the common stock issued	2,311
Transaction costs	165
Total consideration	$ 4,272

Composition of Certain Financ_3

Composition of Certain Financial Statement Captions - Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventories, net [Abstract]
Raw materials	$ 758	$ 681
Work in process	555	722
Finished goods	1,634	1,780
Inventories, net	$ 2,947	$ 3,183

Composition of Certain Financ_4

Composition of Certain Financial Statement Captions - Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Current Assets [Abstract]
Prepaid supplies or services, current	$ 440	$ 544
Prepaid insurance	564	556
Prepaid consumption tax in Japan	19	99
Other receivables	91	112
Total other current assets	$ 1,114	$ 1,311

Composition of Certain Financ_5

Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property and Equipment, net [Abstract]
Manufacturing and development equipment	$ 3,753	$ 4,507
Office and computer equipment	1,242	1,805
Leasehold improvements	2,535	5,087
Property and equipment, gross	7,530	11,399
Less accumulated depreciation	(4,971)	(8,347)
Property and equipment, net	$ 2,559	$ 3,052

Composition of Certain Financ_6

Composition of Certain Financial Statement Captions - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Composition Of Certain Financial Statement Captions [Abstract]
Depreciation expense	$ 0.8	$ 0.9

Composition of Certain Financ_7

Composition of Certain Financial Statement Captions - Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Assets [Abstract]
Long-term supplies	$ 1,540	$ 2,181
Deposits	365	389
Total other assets	$ 1,905	$ 2,570

Composition of Certain Financ_8

Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable and Accrued Expenses [Abstract]
Accrued expenses	$ 1,191	$ 1,599
Accounts payable	720	1,297
Accrued payroll and bonus	554	810
Accrued legal fees	186	509
Accrued vacation	192	64
Accrued R&D studies	230	286
Other current liabilities	284	225
Accounts payable and accrued expenses, Total	$ 3,357	$ 4,790

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Oct. 29, 2018	Aug. 31, 2018	Feb. 27, 2017	Dec. 31, 2018	Dec. 31, 2017	Apr. 27, 2018	Jan. 27, 2017
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months				$ 8,653
Contractual obligation				14,743
Initial term of lease			63 months
Lease commencement date			Jan. 1, 2018
Buy-out of obligations lease			$ 600
Common stock, aggregate amount				$ 15	$ 6
Lorem Vascular [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Percentage of common stock to be purchased						5.00%
Common stock, aggregate amount						$ 5,000
Amended complaint dismissal date				Oct. 1, 2018
Bimini Technologies LLC | Demand for Arbitration [Member] | Sale and Exclusive License/Supply Agreement [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Potential milestone payment due upon acheivement of gross profit		$ 1,000
Gross profit from sale of company’s puregraft product line		10,000
Potential milestone payment claimed		$ 1,000
Proceeds from milestone payment	$ 1,000
Japan Lease [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease							61 months
Lease commencement date				Apr. 15, 2017
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months				$ 1,800
Contractual obligation				3,000
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Rent expense				$ 1,900	$ 2,200

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Debt and Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2019	$ 8,653
2020	6,090
Total	14,743
Payment on Lease Office and Manufacturing Space [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2019	1,282
2020	638
2021	638
2022	192
Total	$ 2,750

Term Loan Obligations (Details)

Term Loan Obligations (Details) - USD ($)	Dec. 31, 2018	Aug. 31, 2018	Jun. 19, 2018	Dec. 29, 2017	Nov. 28, 2017	May 29, 2015	Dec. 31, 2018	Dec. 31, 2017	May 24, 2018	May 23, 2018	Sep. 20, 2017
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)									2,300,000	23,400,000
Date from which warrants are exercisable					May 18, 2018
Minimum cash/cash equivalents covenant	$ 2,000,000						$ 2,000,000
Net proceeds excess receives from unrestricted cash							4,000,000
Interest expense							1,922,000	$ 2,049,000
Non-cash amortization							$ 600,000	$ 700,000
LIBOR [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate						1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date							May 29, 2015	May 29, 2015
Original Loan Amount	$ 17,700,000					$ 17,700,000	$ 17,700,000	$ 17,700,000
Basis variable rate						7.95%
Maturity date	Jun. 1, 2019						Jun. 1, 2019
Fees amount associated with loan						$ 1,100,000
Number of shares callable by warrants (in shares)						9,444
Warrant exercise price (in dollars per share)						$ 103.50
Date from which warrants are exercisable							Nov. 30, 2015
Warrant expiration date							May 29, 2025
Minimum cash/cash equivalents covenant	$ 2,000,000					$ 5,000,000	$ 2,000,000				$ 1,500,000
Extended interest-only period	Jun. 1, 2020	Dec. 31, 2018	Dec. 1, 2018				Aug. 1, 2018
Debt instrument, interest-only period	The Amendment also requires that the Company achieve one of the following by January 31, 2019: enter into an asset sale agreement with a minimum unrestricted net cash proceeds to the Company of $4.0 million; enter into a binding agreement for the issuance and sale of its equity securities or unsecured convertible subordinated debt which would result in unrestricted gross cash proceeds of not less than $7.5 million; or enter into a merger agreement pursuant to which the obligations under the Loan Agreement would be paid down to a level satisfactory to Oxford.	The Third Amendment extends the interest-only period under the Term Loan to December 31, 2018 and also requires that the Company pay to Oxford, in accordance with its pro rata share of the loans, 75% of all proceeds received (i) from the issuance and sale of unsecured subordinated convertible debt, (ii) in connection with a joint venture, collaboration or other partnering transaction, (iii) in connection with any licenses, (iv) from dividends (other than non-cash dividends from wholly owned subsidiaries) and (v) from the sale of any assets (such requirement, the “Prepayment Requirement”).	The Second Amendment extends the interest-only period under the Term Loan to December 1, 2018 if the Company receives unrestricted gross cash proceeds of at least $15 million from the sale and issuance of the Company’s equity securities on or before August 31, 2018.				The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017
Net proceeds excess receives from unrestricted cash				$ 5,000,000
Amendment fee	$ 350,000	$ 50,000	$ 250,000
Percentage of proceeds received		75.00%
Minimum amount to be paid pursuant prepayment requirement		$ 7,000,000
Debt instrument prepayment, description		The Prepayment Requirement does not apply to proceeds from the sale and issuance of the Company’s equity securities, other than convertible debt. The Prepayment Requirement shall apply until an aggregate principle amount of $7.0 million has been paid pursuant to the Prepayment Requirement. However, if less than $7.0 million has been paid pursuant to the Prepayment Requirement on December 31, 2018 then the Company is required to promptly make additional payments until an aggregate principal amount of $7.0 million has been paid.
Debt instrument, covenant compliance							we were in compliance with all of the debt covenants under the Loan and Security Agreement
Minimum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Interest rate						8.95%
Net proceeds excess receives from unrestricted cash	4,000,000
Unrestricted gross cash proceeds required to extend interest-only period	7,500,000		$ 15,000,000
Maximum [Member]
Debt Instrument [Line Items]
Unrestricted gross cash proceeds required to extend interest-only period							$ 7,500,000
Maximum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Original Loan Amount	$ 3,000,000						$ 3,000,000

Term Loan Obligations - Term Lo

Term Loan Obligations - Term Loan Outstanding (Details) - Term Loan [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017		May 29, 2015
Additional details relating term loan that is outstanding [Abstract]
Origination Date		May 29, 2015		May 29, 2015
Original Loan Amount		$ 17,700		$ 17,700		$ 17,700
Interest Rate	[1]	8.95%		8.95%
Current Monthly Payment		$ 100	[2]	$ 100	[3]
Original Term		48 months		48 months
Remaining Principal (Face Value)		$ 12,980		$ 12,980
[1]	3 month LIBOR rate with a floor of 1% plus 7.95%
[2]	Monthly payment as of December 2018, which reflects interest only
[3]	Monthly payment as of December 2017, which reflects interest only

Term Loan Obligations - Future

Term Loan Obligations - Future Minimum Debt and Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
Future contractual principal and final fee payments on all debt and capital lease obligations [Abstract]
2019	$ 8,653
2020	6,090
Total	$ 14,743

Term Loan Obligations - Face Va

Term Loan Obligations - Face Value to Book Value Reconciliation (Details) $ in Thousands	Dec. 31, 2018USD ($)
Reconciliation of Face Value to Book Value [Abstract]
Total debt and lease obligations, including final payment fee (Face Value)	$ 14,743
Less: Debt discount	(541)
Total obligation	$ 14,202

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Provision or benefit for income taxes	$ 0	$ 0
Income Tax Contingency [Abstract]
Valuation allowance	101,091,000	$ 97,089,000
Increase (decrease) in valuation allowance	$ 4,000,000
Corporate income tax rate	21.00%	34.00%
Net tax expense related to remeasurement of deferred tax assets and liabilities due to enactment-date effect of act	$ 0	$ 0
Net operating loss carryforwards, Expire date	Begin to expire in 2019 and 2028
State tax credit carryforwards	$ 4,500,000
Cumulative change in ownership	50.00%
Period of net operating loss and R&D tax credit carry forwards to offset future taxable income	3 years
Provisional amount of remeasured deferred tax assets and liabilities due to change in tax rate fully offset by valuation allowance		45,800,000
Liability for uncertain tax positions	$ 0	$ 0
Period for material changes of liability for uncertain tax benefits	12 months
Interest related to unrecognized tax benefits in interest expense and penalties	$ 0
Maximum [Member]
Income Tax Contingency [Abstract]
Corporate income tax rate		35.00%
Federal [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards	380,600,000
Federal tax carry forward	$ 5,200,000
Federal tax credit carryforward, Expiration date	Begin to expire in 2019
Net operating losses	$ 13,100,000
Federal [Member] | Maximum [Member]
Income Tax Contingency [Abstract]
Percentage of federal net operating losses used to offset of future taxable income	80.00%
State [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards	$ 156,800,000

Income Taxes - Components of In

Income Taxes - Components of Income/(Loss) Before Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S.	$ (12,240)	$ (21,915)
Foreign	(394)	(771)
Income/(loss) before income tax provision (benefit)	$ (12,634)	$ (22,686)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Total Income Tax Provision (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of the total income tax provision tax rate [Abstract]
Income tax expense (benefit) at federal statutory rate	(21.00%)	(34.00%)
Income tax expense (benefit) at state statutory rate	(5.80%)	(3.90%)
Change in valuation allowance	31.80%	(172.40%)
Change in state rate	(0.10%)	(0.80%)
Permanent interest adjustments	0.50%	0.20%
Stock compensation	1.30%	3.00%
Research credit	(1.00%)	(1.10%)
Foreign rate differential		202.10%
NOLs expiring and adjustments to NOL		7.00%
Mark to market adjustment	(3.70%)
Other, net	(2.00%)	(0.10%)
Total income tax provision	0.00%	0.00%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets [Abstract]
Allowances and reserves	$ 270	$ 140
Accrued expenses	122	154
Stock based compensation	996	1,065
Net operating loss carryforwards	91,197	87,426
Income tax credit carryforwards	8,671	8,587
Property and equipment, principally due to differences in depreciation	548	514
Other, net	38	45
Deferred tax assets (Total)	101,842	97,931
Valuation allowance	(101,091)	(97,089)
Total deferred tax assets, net of allowance	751	842
Deferred tax liabilities [Abstract]
Intangibles assets	(751)	(842)
Total deferred tax liability	(751)	(842)
Net deferred tax assets (liability)	$ 0	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]
Unrecognized Tax Benefits – Beginning	$ 2,157	$ 2,062
Gross increases – tax positions in prior period	1	0
Gross decreases – tax positions in prior period	(3)	0
Gross increase – current-period tax positions	61	95
Unrecognized Tax Benefits – Ending	$ 2,216	$ 2,157

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Discretionary or matching contributions	$ 0	$ 0

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock (Details) - USD ($)	Jul. 25, 2018	Jul. 17, 2018	Nov. 28, 2017	Nov. 02, 2017	Dec. 31, 2018	Dec. 31, 2017	May 24, 2018	May 23, 2018	Nov. 27, 2017
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)					5,000,000	5,000,000	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)					$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)					30,223	30,223
Preferred stock, shares outstanding (in shares)					4,606	2,431
Number of shares callable by warrants (in shares)							2,300,000	23,400,000
Common stock issued (in shares)	6,723		10,000
Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)	1		1,800,000
Warrant exercise price (in dollars per share)	$ 0.7986		$ 3.333
Common stock issued (in shares)	6,723		10,000		4,608,453	1,223,708
2017 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights				$ 0
Number of shares callable by warrants (in shares)				10,000
Warrant exercise price (in dollars per share)				$ 3.333
Period exercisable from the date of issuance					30 months
Common stock issued (in shares)			10,000
Gross proceeds from private placement of stock			$ 8,800,000
Redemption price of warrant prior to expiration					$ 0.01
Common stock price per share for warrant redemption					$ 8.33
Number of consecutive trading days for warrant redemption					10 days
2017 Rights Offering [Member] | Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)				18,000,000
Number of warrants exercisable				10
2017 Rights Offering [Member] | Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)				1
2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Warrant exercise price (in dollars per share)		$ 0.7986
Period exercisable from the date of issuance					30 months
Common stock issued (in shares)	6,723
Gross proceeds from private placement of stock	$ 5,700,000
Redemption price of warrant prior to expiration					$ 0.01
Common stock price per share for warrant redemption					$ 3.63
Number of consecutive trading days for warrant redemption					20 days
2018 Rights Offering [Member] | Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1,050
Warrant exercise price (in dollars per share)		$ 1,000
2018 Rights Offering [Member] | Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Series A Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)					13,500	13,500
Convertible preferred stock					3.60%	3.60%
Preferred stock, shares outstanding (in shares)					0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)									10,000
Preferred stock, par value (in dollars per share)									$ 0.001
Preferred stock, shares issued (in shares)					10,000	10,000
Preferred stock, shares outstanding (in shares)					1,112	2,431
Number of shares callable by warrants (in shares)			18,000,000
Common stock issued (in shares)			3,000,000
Series B Convertible Preferred Stock [Member] | 2017 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)				10,000
Series C Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)	7,000
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares outstanding (in shares)					3,494	0
Number of shares callable by warrants (in shares)	7,059,150
Number of share converted into common stock for each share (in shares)	1,253
Series C Convertible Preferred Stock [Member] | Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable					$ 2,500,000
Series C Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		20,000
Common Stock and Series B Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights		$ 0

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	Sep. 21, 2018	Jul. 25, 2018	Jun. 01, 2018	Nov. 28, 2017	May 31, 2017	Apr. 11, 2017	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Common Stock [Abstract]
Common stock issued (in shares)		6,723		10,000
Common stock issued, value									$ 1,624,000	$ 12,716,000
Common Stock [Member]
Common Stock [Abstract]
Common stock issued (in shares)		6,723		10,000					4,608,453	1,223,708
Share issued, price per share						$ 11
Common stock issued, value									$ 5,000	$ 1,000
Common Stock [Member] | Maxim Group LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)					84,900	900,000
Share issued, price per share					$ 11	$ 10.40
Proceeds from sale of common stock, net					$ 800,000	$ 8,700,000
Closing of offering date						Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter						45 days
Additional shares of common stock						94,400
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]
Common Stock [Abstract]
Common stock issued (in shares)								3,900,000
Proceeds from sale of common stock, net								$ 1,700,000
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net			$ 6,500,000
Common Stock [Member] | B. Riley FBR [Member] | ATM Program [Member] | Sales Agreement [Member]
Common Stock [Abstract]
Common stock issued (in shares)								3,900,000
Proceeds from sale of common stock, net								$ 1,700,000
Common Stock [Member] | B. Riley FBR [Member] | ATM Program [Member] | Sales Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Proceeds from sale of common stock, net			$ 6,500,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value	$ 5,000,000
Period exercisable from the date of issuance	24 months
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Securities Purchase Agreement [Member]
Common Stock [Abstract]
Trading Volume of Common Shares	0
Upper Limit on the Price Per Share	$ 0
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding	4.99%
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member] | Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued (in shares)	250,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Minimum [Member] | Single Regular Purchase [Member]
Common Stock [Abstract]
Common stock issued, value	$ 1,000,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member]
Common Stock [Abstract]
Common stock issued (in shares)							600,000
Proceeds from sale of common stock, net							$ 300,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member] | Purchase Agreement [Member] | Maximum [Member]
Common Stock [Abstract]
Floor price of per share	$ 0.25

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	May 31, 2018	May 31, 2017	Jan. 31, 2017	May 31, 2016	Dec. 29, 2015	Aug. 31, 2015	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Securities remaining and available for future issuances (in shares)							1,005,706
Stock Option Activity [Abstract]
Stock option vesting period							4 years
Stock option contractual term							10 years
Stock option vesting provisions							12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or 1/48 of the award will vest at the end of each month over a four-year period.
Weighted Average Remaining Contractual Terms [Abstract]
Stock options exercised							$ 0	$ 0
Dividend yield assumed							0
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards							$ 200,000
Weighted average period for recognition of cost							1 year 6 months
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)	750,000	200,000		33,333		30,180	26,500
Securities remaining and available for future issuances (in shares)							947,856
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)			25,000		6,666
Securities remaining and available for future issuances (in shares)							171

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Options [Roll Forward]
Balance as of January 1, 2018 (in shares) | shares	100,870
Granted (in shares) | shares	117,300
Expired (in shares) | shares	(1,033)
Cancelled/forfeited (in shares) | shares	(79,590)
Balance as of December 31, 2018 (in shares) | shares	137,547
Weighted Average Exercise Price [Roll Forward]
Balance as of January 1, 2018 (in dollars per share) | $ / shares	$ 119.25
Granted (in dollars per share) | $ / shares	2.16
Expired (in dollars per share) | $ / shares	771.07
Cancelled/forfeited (in dollars per share) | $ / shares	5.93
Balance as of December 31, 2018 (in dollars per share) | $ / shares	$ 80.07

Stock-based Compensation - St_2

Stock-based Compensation - Stock Options Vested and Expected to Vest (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Options [Roll Forward]
Balance as of December 31, 2018	137,547	100,870
Vested and expected to vest at December 31, 2018	122,637
Exercisable at December 31, 2018	64,836
Weighted Average Exercise Price [Roll Forward]
Balance as of December 31, 2018 (in dollars per share)	$ 80.07
Vested and expected to vest at December 31, 2018	88.94
Exercisable at December 31, 2018	$ 161.99
Weighted Average Remaining Contractual Term [Roll Forward]
Balance as of December 31, 2018	7 years 10 months 24 days
Vested and expected to vest at December 31, 2018	7 years 9 months 10 days
Exercisable at December 31, 2018	6 years 7 months 2 days

Stock-based Compensation - Weig

Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]
Expected term	7 years 1 month 6 days	6 years 7 months 6 days
Risk-free interest rate	2.94%	2.20%
Volatility	92.87%	78.84%
Resulting weighted average grant date fair value (in dollars per share)	$ 1.74	$ 1.05

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost Recognized for Stock Options and Restricted Stock Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Compensation cost recognized for the stock options and restricted stock awards [Abstract]
Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0)	$ 355	$ 753

Stock-based Compensation - Co_2

Stock-based Compensation - Compensation Cost Recognized for Stock Options and Restricted Stock Awards (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total compensation cost for share-based payment arrangement, Net of tax	$ 0	$ 0

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of year		$ 167	$ 167
Additions	[1]	18	0
Deductions	[2]	0	0
Balance at end of year		$ 185	$ 167
[1]	Includes charges to costs and expenses
[2]	Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers